What is Solvemed?
Solvemed Group operates within the Information Technology and Services sector, focusing on neurodegenerative diseases, particularly dementias. The company utilizes proprietary machine learning technology to pioneer digital biomarkers for neurological drug development. Furthermore, Solvemed is committed to establishing accessible clinical examination and remote monitoring tools, positioning itself at the intersection of healthcare innovation and advanced technology. Headquartered in London, England, Solvemed is driving advancements in digital health solutions.
How much funding has Solvemed raised?
Solvemed has raised a total of $3.5M across 1 funding round:
Other Financing Round
$3.5M
Other Financing Round (2022): $3.5M with participation from Techni Ventures, Tensor Ventures, Atmos Ventures, and APEX Ventures
Key Investors in Solvemed
Techni Ventures
Techni Ventures is an investment firm focused on supporting various ventures, aiming to foster growth and innovation through expertise in venture management.
Tensor Ventures
Tensor Ventures is a venture capital firm specializing in deep tech innovations like AI and biotech, targeting niche startups in Seed and Series A rounds.
Atmos Ventures
ATMOS Ventures is a Deep Tech Venture Capital firm investing in innovative teams tackling complex scientific challenges, with a focus on robotics, AI, and quantum computing.
What's next for Solvemed?
With a substantial enterprise-level funding context, Solvemed is poised for significant scaling and further development of its digital biomarker technology. The recent strategic investment will likely accelerate its efforts in clinical trials support and the expansion of its remote monitoring capabilities. Future growth may involve strategic partnerships within the pharmaceutical industry and further technological refinement to address the growing need for effective neurological disease management and drug development tools.
See full Solvemed company page
